2022-500669-28-00撤回2 期
Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR Trial
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Change in circulating marker of bone resorption (CTX) at 20 weeks.
研究概览
简要总结
to investigate the efficacy and safety of dasatinib plus quercetin or nicotinamide riboside on bone resorption in patients with low bone mass
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Men and women (menopause > 5 years and FSH and LH in the postmenopausal range) aged 60-90 years with a T-score < -1 at the total hip/femoral neck, or lumbar spine (increased risk for developing osteoporosis T-score -1to -2.5, or osteoporosis T-score <-2.5).
- •Ability to provide informed consent
排除标准
- •DXA of hip or spine not possible e.g., due to a prosthesis
- •Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus). If antifungals are necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic.
- •Subjects taking proton pump inhibitors and unwilling to discontinue therapy for two days before and during the study drug dosing periods.
- •Anti-arrhythmic medications known to cause QTc prolongation
- •Tyrosine kinase inhibitor therapy
- •Subjects with an abnormal Complete Blood Count (clinically insignificant changes would be acceptable based on the judgement of the investigators)
- •Subjects on antiplatelet agents (Clopidogrel; Dipyridamole + ASA; ASA, Ticagrelor; Prasugrel; Ticlopidine or other) who are unable or unwilling to reduce or hold therapy prior to and during the study drug dosing periods and collection of bone biopsies. Subjects may continue their previous regimen between study drug dosing periods.
- •Known allergy to dasatinib, quercetin, or NR
- •Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir)
- •Presence of any condition the Investigator believes would place the subject at risk or would preclude the subject from successfully completing all aspects of the trial e.g., heart failure, malignancy etc.
- •QTc >470 msec
- •T-score <-2.5 at the hip or lumbar spine. These individuals may be included if they prefer to participate or are not candidates for conventional osteoporosis therapies
- •Inability to take oral medication
- •Inability to provide fasting blood samples
- •Primary hyperparathyroidism
- •Vitamin D deficiency (<50 nM) (re-test after substitution acceptable)
- •Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe renal impairment (eGFR <20) or liver function (baseline phosphatase higher than twice upper limit, rheumatism, celiac disease/malabsorption, hypogonadism, severe COPD, hypopituitarism, Cushing's disease, uncontrolled diabetes (HbA1c > 58 mmol/mol).
- •Antiresorptive or bone anabolic drugs for the last 3 years
- •Concomitant treatments known to influence bone metabolism e.g., glucocorticoids (systemic treatments), anabolic steroids, etc.
- •Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of dasatinib+quercetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacrolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron
结局指标
主要结局
Change in circulating marker of bone resorption (CTX) at 20 weeks.
Change in circulating marker of bone resorption (CTX) at 20 weeks.
次要结局
- Bone resorption marker tartrate resistant acid phosphatase (TRAcP) at 20 weeks.
- Bone formation markers (PINP, osteocalcin, and bone alkaline phosphatase) at 20 weeks.
研究者
Shakespeare Jeromdesella
Scientific
Odense University Hospital
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR TrialCTIS2022-502076-23-00Odense University Hospital120
进行中（未招募）
1 期
Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR TrialOsteoporosis, OsteopeniaCTIS2022-500669-28-00Odense University Hospital120
进行中（未招募）
2 期
Senolytics to Improve Osteoporosis TherapyOsteopenia, OsteoporosisNCT06018467Odense University Hospital120
已完成
1 期
Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And AtorvastatinOsteoarthritisNCT00411190GlaxoSmithKline32
已完成
2 期
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older HumansHealthyNCT04313634Sundeep Khosla, M.D.74